Safety Study of Oral Edaravone Administered in Subjects With ALS
Status:
Completed
Trial end date:
2021-10-07
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term safety and tolerability of oral
edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.